Finally, the clinical relevance of this work is based on the fact that although RACK1 pharmacological targeting with GCs may be a suitable therapeutic strategy in IBD, particularly in patients with low or no response to GC therapy,92 the novel mechanism of GILZ on RACK1 expression could be considered to improve IBD therapies. This evidence concerns the gene TSC22D3 and inflammatory bowel disease.